xRead - September 2022

Wise et al.

Page 381

Author Manuscript Author Manuscript Author Manuscript Author Manuscript TABLE IX.B.3.b.

Evidence for the role of topical intranasal decongestants in the management of allergic rhinitis Study Year LOE Study design Study groups Clinical endpoint Conclusion Barnes et al. 1330 2005 1b RCT (n = 36): 1 Nasal xylometazoline; 2 Nasal mometasone furoate nPIF, nasal forced inspiratory volume in 1 second, nasal blockage score Xylometazoline was a stronger nasal decongestant than mometasone furoate. Watanabe et al. 1331 2003 1b RCT (n = 30): 1 Oxymetazoline TID; 2 Placebo Subjective nasal blockage, nPIF, airway resistance, airway volume No significant nasal blockage or impaired decongestant response to oxymetazoline following 4-week treatment. Morris et al. 72 1997 1b RCT (n = 50): 1 Daily oxymetazoline; 2 Intermittent oxymetazoline; 3 Placebo Nasal airway resistance, subjective scaling of nasal patency, clinical examination Evidence of rebound nasal congestion was found following 3 days of both daily and intermittent oxymetazoline treatment. Yoo et al. 83 1997 2b Individual cohort study (n = 10): Daily oxymetazoline Subjective history, physical exam, anterior rhinomanometry All subjects remained responsive to oxymetazoline 4 weeks and 8 weeks after the study began.

LOE = level of evidence; nPIF = nasal peak inspiratory flow; RCT = randomized controlled trial; TID = 3 times daily.

Int Forum Allergy Rhinol . Author manuscript; available in PMC 2020 June 10.